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AbstrACt
Objective Undiagnosed HIV continues to be a hindrance to 
efforts aimed at reducing incidence of HIV. The objective of 
this study was to provide an estimate of the HIV undiagnosed 
population in Catalonia and compare the HIV care cascade 
with this step included between high-risk populations.
Methods To estimate HIV incidence, time between 
infection and diagnosis and the undiagnosed population 
stratified by CD4 count, we used the ECDC HIV Modelling 
Tool V.1.2.2. This model uses data on new HIV and AIDS 
diagnoses from the Catalan HIV/AIDS surveillance system 
from 2001 to 2013. Data used to estimate the proportion 
of people enrolled, on ART and virally suppressed in the 
HIV care cascade were derived from the PISCIS cohort.
results The total number of people living with HIV (PLHIV) 
in Catalonia in 2013 was 34 729 (32 740 to 36 827), with 
12.3% (11.8 to 18.1) of whom were undiagnosed. By 2013, 
there were 8458 (8101 to 9079) Spanish-born men who 
have sex with men (MSM) and 2538 (2334 to 2918) migrant 
MSM living with HIV in Catalonia. A greater proportion of 
migrant MSM than local MSM was undiagnosed (32% vs 
22%). In the subsequent steps of the HIV care cascade, 
migrants MSM experience greater losses than the Spanish-
born MSM: in retention in care (74% vs 55%), in the 
proportion on combination antiretroviral treatment (70% vs 
50%) and virally suppressed (65% vs 46%).
Conclusions By the end of 2013, there were an estimated 
34 729 PLHIV in Catalonia, of whom 4271 were still 
undiagnosed. This study shows that the Catalan epidemic of 
HIV has continued to expand with the key group sustaining 
HIV transmission being MSM living with undiagnosed HIV.
IntrOduCtIOn 
Undiagnosed HIV continues to be a 
hindrance to efforts aimed at reducing inci-
dence of HIV. People who remain unaware 
of their HIV status for a long time have an 
increased risk of transmitting the virus to 
others.1 Some studies have shown that undi-
agnosed individuals may give rise to most 
new HIV transmissions,1 2 due to higher 
infectiousness because of elevated viral load 
at the time of HIV seroconversion3 or poor 
decisions related to their risk behaviours.4 
Furthermore, undiagnosed individuals are 
also at risk of delayed diagnosis as they do not 
benefit from timely initiation of combination 
antiretroviral therapy (cART), experience 
higher HIV-related morbidity and higher 
mortality, being 11 times more likely to die 
strengths and limitations of this study
 ► The use of regular surveillance and cohort data 
gives high consistency of local estimates.
 ► The use of the HIV Modelling Tool allowed calculating 
the first step of the HIV care cascade by region of 
origin and among men who have sex with men 
(MSM) in Catalonia.
 ► The various subgroup analyses completed for 
this study may not necessarily explain complex 
differences in global HIV epidemic dynamics among 
migrants and MSM, but they do demonstrate that 
the key group sustaining HIV transmission is MSM 
living with undiagnosed HIV.
 ► Linking surveillance and cohort dataset to population 
migration and death registries is weak in Catalonia; 
therefore, this information is poorly crossed between 
datasets, which can lead to misclassification of vital 
status or out-migration that might overestimate the 
number still alive and living in Catalonia.  on A
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within a year of being tested than if they had been tested 
after they were first exposed.5 
In 2015, it was estimated that around 15%–16% 
(122 000/810 000) of people living with HIV (PLHIV) 
were unaware of their infection in the European Union 
and the European Economic Area (EU/EEA),6 7 with 
proportions ranging from 10% in Sweden,8 12% in 
both the Netherlands and Italy,9 10 17% in UK11 to 34% 
in France.12 Numbers reported from USA are similar to 
those in Western Europe, with 16.4% of the HIV-infected 
individuals being undiagnosed in 2013.13 In previous 
work on the Catalan HIV care cascade, we were not in the 
position to estimate this step, relying on average Euro-
pean estimates.14 The availability of the ECDC model15 
means we now have a tool that is readily available and 
uses routinely available surveillance data to estimate undi-
agnosed HIV, time from infection to diagnosis and esti-
mated annual incidence.
Estimates of the number of people in a country or 
region who have undiagnosed HIV are of paramount 
importance for understanding the burden of HIV, stimu-
lating the early identification and treatment such people 
and informing strategic plans for the future delivery of 
cART.16 On the other hand, the use of the HIV treatment 
cascade as a straightforward guide to quantify popula-
tion-level estimates of successive steps from diagnosis to 
viral suppression will facilitate measurement, monitoring 
and provision of HIV care. Therefore, the objective of 
this study was to provide an estimate of the HIV undiag-
nosed population in Catalonia, taking into account both 
men who have sex with men (MSM) and region of origin, 
using an ECDC model that uses routinely available surveil-
lance data and compare the HIV care cascade with this 
step included between these two high-risk populations.
MethOds
We undertook descriptive and comparative data analysis 
to identify differences in MSM stratified by migrant and 
Spanish-born populations. Migrants were defined as indi-
viduals born in a country other than Spain.
The primary data source was the unified Catalan 
HIV/AIDS surveillance system from 2001 to 2013.17 We 
extracted information on the date of HIV diagnosis, 
sex, age, transmission mode (people who inject drugs, 
heterosexual men, heterosexual women and MSM), 
Figure 1 Model outcomes for the total population in Catalonia, 1980–2013. (A) Estimated annual number of new HIV 
infections. (B) Estimated average time from HIV infection to diagnosis by year of infection. (C) Estimated total number of people 
living with HIV, including diagnosed and undiagnosed HIV infections. (C) Estimated total number of people living with HIV, 
including diagnosed and undiagnosed HIV infections.  Estimated total number of people living with HIV in Catalonia.  
  Estimated total number of people diagnosed with HIV in Catalonia.   Estimated total number of people undiagnosed 
with HIV in Catalonia.
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CD4+ cell count and clinical stage at diagnosis. Late diag-
nosis and advanced HIV infection were defined as a CD4 
cell count below 350 cells/mL or AIDS and CD4 cell 
count below 200 cells/mL or AIDS at the time of HIV 
diagnosis, respectively. Data used to calculate the number 
of PLHIV, the number of undiagnosed and diagnosed 
population and the time between infection and diag-
nosis were the annual number of new HIV diagnoses 
by CD4+ count stratum adjusted for delay in reporting 
and undernotification, the annual number of new AIDS 
cases and the annual number of concurrent HIV/AIDS 
diagnoses (an AIDS diagnosis within 6 weeks of HIV 
diagnosis).
Data used to estimate the proportion of people 
enrolled, on ART and virally suppressed in the HIV care 
cascade were derived from the PISCIS cohort, which 
includes data on over 17 000 HIV-positive people seen for 
follow-up from 1998 (coverage around 80%) in all of the 
participating centres in Catalonia and is fully described 
elsewhere.18 The first two steps of the HIV care cascade 
(PLHIV and diagnosed and proportion of undiagnosed 
population) were derived from the estimates calculated 
with the ECDC tool, whereas the last three were derived 
from the PISCIS cohort. Each of these steps was analysed 
by region of origin and by MSM.
Written informed consent and ethical approval were 
not obtained, as the data used were aggregate anony-
mised surveillance and HIV care information.
stAtIstICAl AnAlysIs
Differences in the distribution of sex, age, transmission 
mode and presentation with late and/or advanced HIV 
disease were assessed by region of origin, using Pearson’s 
χ2 test for categorical variables and Student’s t-test for 
continuous variables.
To estimate HIV incidence, time between infection and 
diagnosis and the undiagnosed population by CD4 count 
strata and its 95% CI, we used the ECDC HIV Modelling 
Tool V.1.2.2,15 which is based on a multistate back-calcu-
lation model that uses surveillance data on new HIV and 
AIDS diagnoses and that models the HIV incidence curve 
by cubic splines. The model is described in detail else-
where.16 19 We considered four distinct historical periods 
for which CD4 stratum-specific diagnosis rates were esti-
mated: (1) 1980–1984, during which the first AIDS cases 
Figure 2 Model outcomes by region origin in Catalonia, 1980–2013. (A) Estimated annual number of new HIV infections among 
Spanish-born population. (B) Estimated annual number of new HIV infections among migrants. (C) Estimated total number 
of Spanish-born people living with HIV, including diagnosed and undiagnosed HIV infections. (D) Estimated total number of 
migrants living with HIV, including diagnosed and undiagnosed HIV infections.  Etimated total number of people living with 
HIV by origin in Catalonia.   Estimated total number of people diagnosed with HIV by origin in Catalonia.  Estimated 
total number of people undiagnosed with HIV by origin in Catalonia.
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were diagnosed; (2) 1985–1998, when serological testing 
for HIV became widely available; (3) 1999–2001, the start 
of the era of combination antiretroviral therapy (cART); 
(4) 2002–2013, the start of the HIV notification in Cata-
lonia. Annual numbers of HIV diagnoses were available 
from 2001 onwards. The CD4 count at the time of diag-
nosis was defined as the first CD4 count after diagnosis 
and before start of treatment. Overall, 81.6% of the 
patients diagnosed from 2001 onwards had a CD4 count 
available at the time of diagnosis. The estimated annual 
numbers of diagnoses by CD4 count stratum were then 
fitted to the observed numbers. The number of HIV-in-
fected who were still alive by the end of 2013 was esti-
mated by subtracting the cumulative number of people 
who died from the cumulative number of HIV infections. 
The number of deaths among diagnosed people was 
taken from the Catalan HIV Surveillance System from 
2001 to 2013.
The subsequent step of linked to care was calculated 
by applying to the preceding stage a proportion esti-
mated from surveillance data. The proportions retained 
in care, on cART and virally suppressed were derived 
from the PISCIS cohort. A fuller description of the 
methods used has been published elsewhere.14 The level 
of significance was set at P value <0.05. Data analysis 
was performed using Stata V.12 (Stata, College Station, 
Texas, USA).
results
There were 10 150 new HIV diagnoses in adults (>18 
years of age) reported to the Catalan National Surveil-
lance System from 2001 to 2013; 60% of the cases were 
Spanish-born, 80.2% were men and the median age was 
35 years old. The epidemiological profile of migrants was 
different to that of the Spanish-born population; there 
was a higher proportion of women (24.6% and 16.7%, 
respectively) and were younger at diagnosis (median age 
of 33 vs 37, respectively). In both migrants and the Span-
ish-born groups, the most frequent at-risk population was 
MSM (40% and 43%, respectively) (online supplemen-
tary table A).
Between 1980 and 2013, a cumulative number of 41 364 
(95%  CI 35 299 to 44 990) infections in the Catalan popu-
lation were estimated to have occurred. The estimated 
number of new HIV infections peaked around 1988 with 
3124 (95% CI 3031 to 3159) (figure 1A), declining nearly 
sevenfold, from 2674 (95% CI 2388 to 2663) in 1990 to 
391 (95% CI 188 to 372) in 1999. From 2011, the esti-
mated number of new infections started to peak up again 
reaching levels comparable with those in the mid-1990s, 
with the highest estimated number in 2013, 1120 (95% 
CI 461 to 1324). The estimated mean time between infec-
tion and diagnosis if diagnosis rates remain the same as in 
the year of infection is shown in figure 1B. Between 1980 
and 1983, when HIV could only be diagnosed once AIDS 
symptoms appeared, the estimated average time between 
Table 1 Estimated annual number of new HIV infections and new HIV, HIV/AIDS and AIDS diagnoses reported to the Catalan 
surveillance system, by year of infection and origin in MSM, Catalonia, 2001–2013
Year
Estimated new HIV infection
New HIV diagnoses 




reported to the 
Catalan surveillance 
system
New AIDS diagnoses 
reported to the 
Catalan surveillance 
system













N IC95% N IC95% N N N N N N
2001 134 (108 to 159) 52 (39 to 69) 152 47 45 10 68 16
2002 151 (127 to 172) 74 (63 to 90) 175 62 41 16 55 19
2003 163 (138 to 181) 99 (87 to 113) 158 59 44 20 70 23
2004 172 (156 to 188) 126 (113 to 141) 185 89 28 14 52 23
2005 181 (164 to 196) 152 (137 to 167) 181 91 27 11 36 20
2006 191 (174 to 210) 176 (159 to 192) 187 109 26 18 52 16
2007 204 (190 to 222) 195 (178 to 212) 207 125 26 19 39 34
2008 222 (209 to 238) 209 (195 to 225) 183 133 19 17 35 27
2009 245 (231 to 260) 219 (205 to 237) 191 115 26 13 40 20
2010 274 (255 to 296) 225 (204 to 249) 224 175 24 22 34 38
2011 310 (275 to 347) 228 (196 to 261) 193 243 14 18 27 25
2012 353 (298 to 408) 228 (183 to 283) 282 189 19 10 35 22
2013 404 (322 to 480) 227 (163 to 310) 291 185 19 19 32 28
MSM, men who have sex with men.
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infection and HIV diagnosis for people infected in this 
period, where conditions have remained as they were in 
this period, would have been 11.6 years. This decreased 
to 4.7 years (95% CI 4.4 to 5.0) in the period 1984–1998. 
From 2000 onwards, the estimated time to HIV diagnosis 
steadily decreased to 3.9 (95% CI 3.6 to 4.6) years on 
average for the whole population in 2013. By region of 
origin, in both Spanish-born people and migrants, there 
was a similar decreasing trend in the estimated average 
time from infection to diagnosis until it reached 3.6 
years (95% CI 3.4 to 3.8) and 4.7 years (95% CI 4.6 to 
5.01), respectively in 2013. Figure 1C shows the estimated 
total number of PLHIV in Catalonia from 1980 to 2013, 
including those not yet diagnosed. Overall, there was an 
increasing trend throughout the time period, reaching 
the highest estimated number of people in 2013, a total 
of 34 729 (95% CI 32 740 to 36 827) PLHIV in Catalonia. 
Of these, 4271 (95% CI 3737 to 6252) were undiagnosed, 
a proportion of 12.3% (95% CI 11.8 to 18.1).
In 2013, the estimated number of new infections 
among the Spanish-born population reached a number 
of 744 (95% CI 546 to 934) (figure 2A), while among 
the migrants was 376 new infections (95% CI 281 to 
471). Finally among MSM, in both Spanish-born and 
Figure 3 Model outcomes for the MSM by origin in Catalonia, 1980–2013. (A) Estimated total number of Spanish-born MSM 
living with HIV, including diagnosed and undiagnosed HIV infections. (B) Estimated total number of migrant MSM living with 
HIV, including diagnosed and undiagnosed HIV infections.  Estimated total number of MSM living with HIV by origin in 
Catalonia.  Estimated total number of MSM diagnosed with HIV by origin in Catalonia.  Estimated total number of MSM 
undiagnosed with HIV by origin in Catalonia. MSM, men who have sex with men.
Figure 4 Cascade of HIV care of MSM by region of origin in Catalonia, 2013. (A) Spanish-born MSM. (B) Migrants MSM. 
cART, combined antiretroviral therapy; MSM, men who have sex with men; PLHIV, people living with HIV; VL, viral load.
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migrants, there was a clear stepping increase in the esti-
mated number of new infections from 2001, reaching the 
highest number in 2013, with 404 (95% CI 322 to 480) 
and with 227 (95% CI 163 to 310), respectively (table 1 
and figure 2B).
By he estimated total number of PLHIV comparing 
the trend in the number of PLHIV between migrant and 
Spanish-born groups, it was observed that among locals 
there was a progressive but not very pronounced rise from 
1991 to reach the highest estimated number in 2013 with 
27 648 (95% CI 25 365 to 29 379) PLHIV, just 5.8% (95% 
CI 5.8 to 6.6) of whom were undiagnosed (1603, 95% 
CI 1421 to 1819) (figure 2C and D). Conversely, among 
migrants the estimated number of PLHIV rose steeply 
since the beginning of the epidemic, also reaching a peak 
in 2013 with 7081 (95% CI 6492 to 7616), but with four 
times the estimated undiagnosed population (23.4%, 
95% CI 22.7 to 25.1) compared with the local population. 
Among (figure 3A and B) both local and migrant MSM, 
there has been a large increase in the estimated number 
of MSM living with HIV in the last 10 years, with a higher 
increasing slope among migrant MSM. By 2013, there 
were 8458 (95% CI 8101 to 9079) Spanish-born MSM and 
2538 (95% CI 2334 to 2918) migrant MSM living with 
HIV in Catalonia, with 16.4% (95% CI 14.2 to 17.7) and 
32.3% (95% CI 28.4 to 34.4) undiagnosed, respectively.
Data from the PISCIS cohort are available 
in online supplementary table B. Finally, figure 4A and 
B shows the differences in the HIV care cascade in MSM 
by origin. As a percentage of the total PLHIV, migrant 
MSM have a greater proportion undiagnosed (32% vs 
16%) that local MSM. In subsequent steps in the HIV 
care cascade, migrant MSM experience greater losses due 
to the big different in the proportion of undiagnosed, 
when compared with the Spanish-born MSM, with lower 
proportion retained in care (74% vs 55%), on cART (70% 
vs 50%) and virally suppressed (65% vs 46%).
dIsCussIOn
Our study estimates that by the end of 2013, there were 
an estimated number of 34 729 PLHIV in Catalonia, 
Spain, of whom 4271 were still undiagnosed. This study 
also shows that migrants had a very high proportion of 
undiagnosed compared with Spanish-born population, 
and as it has been described by other sources of informa-
tion from Catalonia,17 this study found that the Catalan 
epidemic of HIV has continued to expand during the 
past decade with the key group sustaining HIV transmis-
sion being MSM living with undiagnosed HIV and in the 
asymptomatic stage, especially migrants MSM.
The estimated overall prevalence of undiagnosed 
HIV-infected people in Catalonia (12.3%) is within the 
range of those recently obtained in other countries by 
2013: 10% in Italy, 12% in Austria, 16% in Belgium and 
France, 17% in Germany, 18% in Spain and 19% in UK.7 
Nevertheless, we think that some underestimation may 
have occurred due to two facts: first, that the method 
that we applied uses data on case reports, which may be 
subject to under-reporting, which can be ranged between 
10% and 40%20 21 and can lead to underestimates HIV 
incidence and may also affect estimates of diagnosis rates 
and thus lower the per cent undiagnosed and second, 
by the fact that we could not feed the model with migra-
tion data. As Catalan epidemic is highly influenced by 
migration, we believe that this lowers the estimates of 
the annual number of new HIV infections and therefore 
undiagnosed HIV-infected individuals.
In line with our results, other studies also had identified 
among migrants a great proportion of undiagnosed.22 23 In 
Catalonia, this could be explained by the fact that migrants 
experienced a higher number of barriers to access HIV 
testing services than the Spanish-born population and 
that these needs might be driven primarily by shared risk 
factors.24 This also can be due to the fact that migrants 
face cultural and linguistic barriers as well as legal and 
administrative impediments to accessing health services 
and thus HIV testing facilities.25 In Europe, the HIV 
testing uptake among migrants range from 23% to 64%.25 
This difference can differ by sex, as higher proportion 
of migrant women have been tested for HIV compared 
with men; this is partially owing to women’s acceptance of 
routine HIV screening during antenatal care. However, 
beyond this, several studies support a gender difference in 
HIV testing uptake, with migrant men being less exposed 
to HIV testing and less willing to be tested.25 However, 
this lower rate of HIV testing among migrant men might 
be more representative of migrant heterosexual men that 
MSM migrants, as these later perceive themselves as being 
at higher risk for HIV and thus being more likely to have 
ever been tested for HIV than the local MSM.26 27 But, it 
has been found that untested migrant MSM are particu-
larly hard to reach,27 which is in line with our estimates.
Our results suggest that the Catalan HIV epidemic has 
been sustained by the HIV transmission among undiag-
nosed MSM, as it has been described in other studies in 
Catalonia.28 29 Consistent with this, in UK, using the same 
model it has been estimated that around two in three new 
infections were attributable to MSM living with undiag-
nosed HIV,30 and in Switzerland that around 82% of new 
cases among MSM were acquired from HIV undiagnosed 
men.31 This finding can be explained by an increase in 
risky sexual behaviours,32 33 including high prevalence of 
unprotected anal intercourse and increasing numbers of 
sexual partners.34 This is also supported by a recent survey 
that reported that 37% of MSM recruited in gay venues 
had not tested for HIV in the past 12 months.32 It has also 
been described that a great proportion of undiagnosed 
MSM have acquired the infection recently, which made 
them to be most infectious and the maintenance group 
of the HIV epidemic.34 The risky sexual conducts among 
migrant MSM have been also described, with higher prev-
alence of unprotected anal intercourse than Spanish-born 
MSM35 36 and specifically among Latin American MSM, 
high HIV prevalence rates among those diagnosed with 
syphilis and gonorrhoea, as well as, with high prevalence 
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and incidence rates of STIs in those newly diagnosed 
with HIV.35 Resources should be allocated primarily to 
promote testing in high-activity MSM, as they are the 
key group sustaining the epidemic, and also for encour-
aging all MSM including migrants MSM to test regularly 
for HIV, and this includes design long-term sustainable 
outreach-based HIV interventions to reach as many MSM 
as we could for HIV testing.
Biomedical and behavioural interventions, targeting 
both HIV-infected and HIV-uninfected MSM, should be 
used. In this regard, it will be essential to use interven-
tions with proven efficacy, such as treatment as preven-
tion, test and treat interventions, in combination with 
pre-exposure prophylaxis in highly adherent people, and 
to implement effective behavioural interventions that 
prevent an increase in risky behaviours, all of these inter-
vention must be integrated in a well-designed strategy of 
combination prevention, as it has been described in other 
studies.37 Thus, in order to reduce the fraction of undi-
agnosed should be considered implementing and scaling 
up innovative approaches to promote greater access to 
and uptake of HIV testing by those most at risk, including 
community-based testing, home sampling, as well as indi-
cator-condition-guided testing.
These results must be interpreted in light of several key 
methodological limitations. The use of the HIV Model-
ling Tool facilitated the standardisation of estimates for 
PLHIV; however, available information is partial and not 
representative of the different subpopulations of migrants 
and MSM across all Catalonia. Despite this limitation, this 
analysis allowed us to calculate the first step of the HIV 
care cascade by region of origin and among MSM in Cata-
lonia. The various subgroup analyses completed for this 
study may not necessarily explain complex differences in 
global HIV epidemic dynamics among migrants and MSM, 
but they do demonstrate that the key group sustaining 
HIV transmission is MSM living with undiagnosed HIV 
and that among migrants testing coverage will need to 
be intensified and increased to find those undiagnosed. 
Although the use of PISCIS cohort data improved the 
consistency of the estimates, we are unable to link surveil-
lance and cohort datasets to maximise internal consis-
tency; therefore, we are unable to distinguish between 
those diagnosed and those linked to care (enrolled in 
the cohort), although linkage to care is expected to be 
high given the Catalan healthcare system characteristics 
and the high cohort coverage. Additionally, using a single 
viral load measurement may also overestimate durable 
viral suppression; however, they provide a snapshot of 
the continuum in 2013 which is simple to interpret and 
communicate to policy-makers, as it has been described by 
other authors.7 38 Finally, linking surveillance and cohort 
dataset to population migration and death registries is 
weak in Catalonia; therefore, this information is poorly 
crossed between datasets, which can lead to misclassifi-
cation of vital status or out-migration that might overesti-
mate the number still alive and living in Catalonia. Also, 
lack of reliable in-migration data complicated modelling 
of HIV incidence and the separation of earlier infections 
from new infections occurring after arrival within Catal-
onia. This demonstrates the urgent need to systematically 
incorporate longitudinal linked data across the different 
registries in the HIV information system aimed at moni-
toring and evaluate the HIV epidemic and its response at 
the local level.
In conclusion, our study suggests that about 4271 
individuals living with HIV remained undiagnosed in 
Catalonia in 2013, with the greatest proportion among 
migrants and MSM from abroad and local. New screening 
strategies to further increase the offer and uptake of HIV 
testing and to reach out undiagnosed individuals are 
needed in order to reduce HIV transmission, targeting 
key population like migrants and MSM to ensure timely 
access to HIV care, to finally achieve global 90-90-90 
targets to reduce HIV incidence and the number of 
persons remaining undiagnosed in Catalonia.
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